Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …

Autoimmune diseases, including psoriasis, systemic lupus erythematosus (SLE), and
rheumatic arthritis (RA), are caused by a combination of environmental and genetic factors …

Background Secukinumab has demonstrated sustained long‐term efficacy with a favourable
safety profile in various psoriatic disease manifestations in adults. Objectives Here, the …

Corticosteroids are the mainstay of therapy for many pediatric disorders and sometimes are
life-saving. Both endogenous and synthetic derivatives diffuse across the cell membrane …

Background Psoriasis affects 0.13%-2.1% of children and adolescents. Despite a high
unmet need, the current treatment options approved for pediatric psoriasis are limited …

Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide
variety of indications since then. However, despite widespread off‐label use, FDA labeling …

Summary Background Adalimumab (ADA)(Humira®, AbbVie Inc., USA) is approved by the
European Medicines Agency for children aged≥ 4 years with severe plaque psoriasis …

Biologic therapies like adalimumab are the gold standard for psoriasis treatment with
efficacy and safety profiles allowing for long-term treatment. However, adalimumab cannot …

Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence
ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with …

Background Psoriasis is a chronic inflammatory disease with clinical manifestations of the
skin that affect adults and children. In adults, biologics have revolutionized the treatment of …